Key facts
- It has raised $7.6M; the latest was Later Stage VC in Sep 2026.
- Notable investors include Innovate UK, SOSV, MedTech Innovator, HAX, CVX Ventures — 24 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 24 names
- ·Watchlist + deal alerts for Samphire Neuroscience
- ·The full record, as it builds
Funding rounds
No funding rounds for Samphire Neuroscience are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Samphire Neuroscience
Developer of non-invasive neurotechnology therapeutics designed to address hormonally mediated conditions with unmet clinical need, operating in the women's health and neuromodulation domain. The company offers brain-based wearable devices and a supporting platform using clinically validated transcranial direct current stimulation protocols, proprietary neuromodulation programs, and regulated clinical deployment across medical and consumer settings, enabling patients and healthcare providers to access drug- and hormone-free options for managing premenstrual, menstrual, and chronic pelvic pain conditions.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2021
- Employees
- 21
- Website
- samphireneuro.com/
- Ownership
- Privately Held (backing)
Samphire Neuroscience doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Samphire Neuroscience shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Samphire Neuroscience in its N-PORT filings yet. We sweep new filings monthly.